- Merus N.V. (NASDAQ:MRUS) intends to offer and sell up to $60M of shares of its common stock in an underwritten public offering.
- Underwriters have a 30-day option to purchase up to an additional $9M worth of stock.
- The company intends to use the net proceeds from this offering to advance the clinical development of its product candidates, for preclinical research and technology development, and working capital and general corporate purposes.
After climbing ~6.0% today, the shares have lost 6.9% in after-hours trading.